Oxcarbazepine (All indications)

Language disorders/delay

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12798
R48221		 Meador (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) 3rd trimester prospective cohort exposed to other treatment, sick excluded Adjustment: Yes extrapolated (cont. endpoint) 1.40 [0.49;4.02]
excluded (control group) 		-/13   -/93 - 13
ref
S12799
R48222		 Meador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) 3rd trimester prospective cohort unexposed, disease free Adjustment: Yes extrapolated (cont. endpoint) 1.36 [0.47;3.92] -/13   -/87 - 13
ref
S10097
R36770		 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Visits to a speech therapist (mean age of 3.7 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes Controls: mixed indications 1.30 [0.70;2.50]
excluded (control group) 		13/143   157/2,916 170 143
ref
S9087
R31120		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Health care utilization: Speech therapy (mean age of 3.6 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.70 [1.00;2.90] 13/143   72,012/1,710,441 72,025 143
ref
S9939
R35727		 Videman (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2016 Griffiths Mental Developmental Scale - Hearing and speech (at the age of 7 months) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) 2.11 [0.38;11.63]
excluded (control group) 		-/10   -/8 - 10
ref
S9940
R35733		 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 Griffiths Mental Developmental Scale - Hearing and speech (at the age of 7 months) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No extrapolated (cont. endpoint) 9.58 [2.67;34.33] -/10   -/59 - 10
ref
Total 3 studies 2.52 [0.94;6.73] 72,025 166
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Meador (Oxcarbazepine) (Controls unexposed, disease free), 2021Meador, 2021 1 1.36[0.47; 3.92]-1331%ROB confusion: moderateROB selection: lowROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: low Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 2 1.70[1.00; 2.90]72,02514342%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016Videman, 2016 3 9.58[2.67; 34.33]-1027%ROB confusion: unclearROB selection: lowROB classification: moderateROB missing: criticalROB mesure: lowROB reporting: moderate Total (3 studies) I2 = 70% 2.52[0.94; 6.73]72,0251660.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, disease free; 2: Oxcarbazepine) (Controls unexposed, NOS; 3: Oxcarbazepine) (Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.52[0.94; 6.73]72,02516670%NAMeador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.52[0.94; 6.73]72,02516670%NAMeador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 3 Tags Adjustment   - No  - No 9.58[2.67; 34.35]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 1   - Yes  - Yes 1.63[1.01; 2.62]72,0251560%NAMeador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 2 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 3.49[0.52; 23.61]-2381%NAMeador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 2 All studiesAll studies 2.52[0.94; 6.73]72,02516670%NAMeador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 30.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9939, 10097, 12798

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.52[0.94; 6.73]72,02516670%NAMeador (Oxcarbazepine) (Controls unexposed, disease free), 2021 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.38[0.82; 2.33]1701660%NAMeador (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Videman (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2016 30.510.01.0